atc sales

current estimate of peak ATC sales is US$600M per year

interesting to compare to FTC revenue for last qtr for gilead

back of the envelope on the gilead numbers below has FTC (thru ftc, 1/2 truvada and 1/3 atripla) revenue at about us$600M PER QTR!



GILEAD 3QTR 09
Product Sales

Product sales increased 23 percent to a record $1.65 billion for the third quarter of 2009, compared to $1.34 billion in the third quarter of 2008. This increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and continued growth in sales of Truvada® (emtricitabine/tenofovir disoproxil fumarate), as well as the addition of Ranexa® (ranolazine) to our commercial portfolio.

Antiviral Franchise

Antiviral product sales increased 19 percent to $1.47 billion in the third quarter of 2009, up from $1.23 billion for the same quarter of 2008. The increase was driven primarily by sales volume growth of Atripla and Truvada.

* Truvada

Truvada sales increased 13 percent to $620.6 million for the third quarter of 2009, up from $549.1 million in the third quarter of 2008, driven primarily by sales volume growth in the United States and Europe.

* Atripla

Atripla sales increased 42 percent to $605.3 million for the third quarter of 2009, up from $427.6 million in the third quarter of 2008, driven primarily by sales volume growth in the United States and Europe.

* Viread

Viread® (tenofovir disoproxil fumarate) sales increased nine percent to $169.7 million for the third quarter of 2009, up from $156.0 million in the third quarter of 2008, driven primarily by sales volume growth in the United States and Europe.

* Other Antiviral Products

Other antiviral product sales which consist of Hepsera® (adefovir dipivoxil) and Emtriva® (emtricitabine) were $74.7 million for the third quarter of 2009.